项与 Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital) 相关的临床试验
ChiCTR1800020064
/ Recruiting临床1/2期IIT
A single-center, single-arm, open-label, dose escalation study for evaluating the safety & preliminary anti-tumor activity of CD19 allogeneic chimeric antigen receptor T cells (CD19 Allo-CAR-T) in the treatment of patients with relapsed / refractory B cell malignancies
开始日期2018-12-01
申办/合作机构-
ChiCTR1800015164
/ SuspendedN/AIIT
multi-center clinical study of CD19+ -car-t cells combined with chemotherapy in the treatment of the newly diagnosed high-risk adult PH (-) B-ALL
开始日期2018-04-01
申办/合作机构-
ChiCTR1800019288
/ Recruiting早期临床1期IIT
A clinical trial for safety and efficient of CD19CART cells combination with nivolumab in the treatment of refractory/relapsed B cell lymphoma
开始日期2017-01-01
申办/合作机构-
100 项与 Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital) 相关的临床结果
登录后查看更多信息
100 项与 Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital) 相关的转化医学
登录后查看更多信息
100 项与 Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital) 相关的专利(医药)
登录后查看更多信息
1
项与 Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital) 相关的文献(医药)